Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2012        Go!    
 
 
January 19, Friday 2018 10:53 PM       

       HEADLINES: Why we need these MPs to talk only in channels, asks K Surendran                                              Hartal in Kannur on Saturday                                              Malayali Jawan killed in Pak ceasefire violation                                              B Sandhya removed as ADGP, South                                              Was son killed over property dispute? Police unwilling to accept Jaya's statement                                              Fire breaks out in Mumbai's Navrang Studio                                              Solution to SC judges’ row likely on Monday                                              EC has never touched this low: AAP                                              Hafiz Saeed should be prosecuted: US                                              India should not comment on Chinese construction in Doklam: Beijing                                              Pak-Iran to resume rail services                                              Kulbhushan Jadhav abducted from Iran: Baloch activist                                              Brazil legend Pele collapses with exhaustion                                              ICC U-19 WC: India thrash Zimbabwe to top Group B                                              We will definitely try to get Ashwin back in CSK: Dhoni                                              AIFF U-16 team departs for exposure trip to Dubai                                              Kaumudi Facebook
       SCI&TECH Next Article: Water exists deeper in Earth than thought: study  
       New potent vaccine may spell end for HIV
 
         Posted on :16:07:12 Nov 28, 2016
   
A A
       Last edited on:16:07:12 Nov 28, 2016
         Tags: New potent vaccine, HIV
 
WASHINGTON: The largest and most advanced HIV vaccine trial has been launched in South Africa to test the safety of a new experimental regimen that could prove to be the final nail in the coffin for the deadly virus.
 
The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus.
 
It aims to enroll 5,400 men and women, making it the where more than 1,000 people become infected with HIV every day.
 
"If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," said Anthony S Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID).
 
"Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa," said Fauci.
 
The HIV Vaccine Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020.
 
The experimental vaccine regimen being tested in the trial is based on the one investigated in the earlier RV144 clinical trial in Thailand led by the US Military HIV Research Programme and the Thai Ministry of Health.
 
The Thai trial delivered landmark results in 2009 when it found for the first time that a vaccine could prevent HIV infection, albeit modestly.
 
The new regimen aims to provide greater and more sustained protection than the RV144 regimen and has been adapted to the HIV subtype that predominates in southern Africa, a region that includes the country of South Africa.
 
"The people of South Africa are making history by conducting and participating in the first HIV vaccine efficacy study to build on the results of the Thai trial," said Glenda Gray, CEO of the South African Medical Research Council.
 
"HIV has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country," Gray said, who is also a professor at the University of the Witwatersrand.
 
"If an HIV vaccine were found to work in South Africa, it may dramatically alter the course of the pandemic," she said. The experimental vaccine regimen tested in the Thai trial was found to be 31.2 per cent effective at preventing HIV infection over the 3.5-year follow-up after vaccination.
 
In the HVTN 702 study, the design, schedule and components of the RV144 vaccine regimen have been modified in an attempt to increase the magnitude and duration of vaccine-elicited protective immune responses.
 
HVTN 702 begins just months after interim results were reported for HVTN 100, its predecessor clinical trial, which found that the new vaccine regimen was safe for the 252 study participants and induced comparable immune responses to those reported in RV144. 
A A
       SCI&TECH
Next Article: Water exists deeper in Earth than thought: study
 
 
SCI&TECH HEADLINES
Secret of longevity protein revealed!  
Absence of this gene can give men deadly cancer  
Soon, you can demote group admins on WhatsApp  
Regular yoga can slow down ageing of brain: Study  
What are haemorrhoids (piles) and what causes them?  
WhatsApp facilitates quick switch from voice to video call  
The Thin and Light Lenovo Ideapad 720s shines at Digit Zero 1 Awards  
Frequent heartburns up cancer risk in older adults  
Blueberry vinegar can help fight dementia  
iPhones with older batteries will take a hit in performance: Apple  
Eighth planet found in faraway solar system, matching ours  
Google brings a host of new features on Pixel 2  
Scientists turn beer into suitable petrol  
Space gives a sense of humbleness: NASA astronaut  
Researchers discover genes to prolong human life  
Google announces best apps of 2017  
This technology can help to reduce accidents on icy roads  
Yepzon launches in India; promises smart safety solutions  
Soon, you'll be able to control diabetes with your phone  
Turning bacteria into 'world's smallest tape recorders'  
How breastmilk protects babies from food allergy decoded  
Stars among the oldest in our galaxy discovered  
Apple delays release of smart speaker - HomePod  
Owning a dog may add years to your life  
'Textisms' actually add meaning to written words  
 
Do you think even today police resort to third degree torture to prove crime?
yes
 
no
 
no opinion
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy